

Double Bond Pharmaceutical to Present Clinical Real-World Evidence Data for SI053 at the 2026 Society for Neuro-Oncology (SNO) Annual Meeting in Philadelphia

UPPSALA, SWEDEN — July 21, 2026 — Double Bond Pharmaceutical AB (publ) (“DBP” or the “Company”) today announced that its abstract highlighting clinical Real-World Evidence (RWE) data for its lead neuro-oncology candidate, **SI053 (Temodex)**, has been accepted for presentation at the 31st Annual Meeting of the Society for Neuro-Oncology (SNO).

The SNO Annual Meeting, widely recognized as the premier global event in neuro-oncology, will take place November 12–15, 2026, at the Pennsylvania Convention Center in Philadelphia, Pennsylvania. As part of the official conference proceedings, the accepted abstract will be published by SNO in a supplement to the premier peer-reviewed journal **Neuro-Oncology**.

"The acceptance of our clinical dataset by the Scientific Program Committee of SNO provides strong external validation of SI053's therapeutic potential," said Igor Lokot, CEO of Double Bond Pharmaceutical. "Presenting our clinical RWE results on a global stage in Philadelphia enables us to engage directly with international neuro-oncology opinion leaders, clinical researchers, and strategic industry partners as we advance SI053 toward pivotal registration steps."

More about the Society for Neuro-Oncology (SNO): SNO is a multidisciplinary organization dedicated to promoting research and education in neuro-oncology. Its annual meeting constitutes one of the premier international forums for the presentation of new clinical and translational research findings regarding malignant CNS tumors (<https://www.soc-neuro-onc.org/meetings-education/sno-conferences>).

More about Real-World Evidence Study: <https://mb.cision.com/Main/12720/4307158/39333333.pdf>

More about SI-053: SI-053, an enhanced reformulation of Temodex, is a locally acting formulation of temozolomide. SI-053 received Orphan Drug Designation from the European Medicines Agency in 2016 and received multiple Competent Authority and Ethics Committee approvals from 2021 to 2023 to initiate a Phase 1 clinical study. In a proof-of-concept study with human subjects conducted in 2015, SI-053 demonstrated significant overall survival benefit when added to the standard of care for glioblastoma. **Video presentation:** <https://youtu.be/iweOQPq316o>

Information about Double Bond Pharmaceutical AB: DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company's own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.

This information is information that Double Bond Pharmaceutical International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above at July 21, 2026.

Full Company Name: Double Bond Pharmaceutical International AB (publ)

Corporate identity: 556991-6082

Stock short name: DBP B

Share ISIN code: SE0007185525

For more info, contact

Igor Lokot, CEO

Homepage: <http://www.doublebp.com/>

E-mail: info@doublebp.com

Follow us on [LinkedIn](#)